FDA grants orphan drug status to Keryx

Keryx Biopharmaceuticals Inc. reported that the FDA gave its developing multiple myeloma drug KRX-0401, or Perifosine, orphan drug status.

The company said a late-stage study is expected to start by the end of 2009.